(The picture shows Wang Donghua, Vice President of Fosun Pharma, and Yang Bo, General Manager of Hongqi Pharmaceuticals, on behalf of Fosun participated in the China National Defense Tuberculosis Public Welfare Fund for the Relief of Tuberculosis Poor Poverty Patients of the China National Defense Tuberculosis Association on behalf of Fosun. Licensing ceremony.)

        In order to allow all tuberculosis patients to receive timely assistance and care, in 2016, the China National Tuberculosis Association established the "China National Tuberculosis Public Welfare Fund", which will be launched in March In the publicity campaign on the Day of Tuberculosis, the Fosun Foundation and Fosun Pharma’s member company Shenyang Hongqi Pharmaceutical Co., Ltd. ("Hongqi Pharmaceutical" for short) jointly launched the China National Defense Tuberculosis Public Welfare Fund——TB Poverty Relief“ Double Thousand Action” project.

         On April 27, 2016, the China National Tuberculosis Association 2016 National Academic Conference was held in Zhuhai City, Guangdong Province, and the China National Tuberculosis Public Welfare Fund was officially unveiled at the opening ceremony. ceremony.

        As a member unit of the China National Tuberculosis Association and the China National Tuberculosis Public Welfare Fund——TB Poverty Relief“Double Thousand Action” one of the initiators of the project, Fosun Public Welfare Fund The meeting, Fosun Pharmaceutical Group and its member company Shenyang Hongqi Pharmaceutical Co., Ltd. ("Hongqi Pharmaceutical" for short) were invited to participate in this conference.

        At the meeting, the China National Tuberculosis Association also awarded the Fosun Charity Foundation and Shenyang Hongqi Pharmaceutical Co., Ltd.——China National Tuberculosis Charity Fund to aid poor tuberculosis patients“Double Thousand The action” project sponsor, Wang Donghua, vice president of Fosun Pharma Group, and representatives of Hongqi Pharmaceutical, spoke at the meeting.

        “Double Thousand Action” The project started in 2016 and lasts for five years from 2020 to 2020. At least 1,000 poor tuberculosis patients can be rescued each year, and each patient’s assistance fund is at least 1,000 yuan. The Fosun Foundation and Hongqi Pharmaceutical, a member company of Fosun Pharma, will continue to support this project and provide various forms of sponsorship such as funds and medicines.

        Wang Donghua said in his speech that the China National Tuberculosis Association has established the “China National Tuberculosis Public Welfare Fund”, and is co-sponsored by the Fosun Foundation and Fosun Pharma’s member company Hongqi Pharmaceutical The tuberculosis poverty relief "Double Thousand Action" project will bring good news to poor tuberculosis patients. This is also the conscious behavior of the company to develop its own gratitude to the society and repay the society. As a member of the health industry, it is precisely because of the pursuit of life to help patients, especially poor patients, get timely assistance, return and regain health and happiness, that will continue to pay attention to and support the cause of tuberculosis in China.

As the country's largest anti-tuberculosis drug research and development and production base, Hongqi Pharmaceutical has made important contributions to the cause of China's tuberculosis defense. Currently, its first-line anti-tuberculosis drugs are Rifampicin Capsules, Rifampicin Capsules II, Isoniazid Tablets, Ethambutol Tablets (Capsules), Pyrazinamide Tablets (Capsules), Prothionamide Enteric-coated Tablets, etc., Sales have always been in the forefront of the country. In particular, FDC (Fixed Dose Combination) products have two kinds of medicines taken daily and every other day. At present, Hongqi Pharmaceutical's anti-tuberculosis drugs have been serialized. Under the background of China's establishment and improvement of a new type of tuberculosis prevention and treatment system, Hongqi Pharmaceuticals will innovate more good products and make greater contributions to the cause of China's tuberculosis defense.